Drug intelligence / Profile preview

Debio 4228

Development stage: Phase 2
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Intramuscular

Overview

Debio 4228 is an extended-release formulation of a gonadotropin-releasing hormone (GnRH) antagonist developed for the treatment of locally advanced or metastatic prostate cancer. It is administered via intramuscular injection and is currently being evaluated in Phase 2 clinical trials to determine its pharmacokinetics and pharmacodynamics. The drug aims to provide continuous androgen deprivation therapy (ADT) by inhibiting GnRH, thereby reducing testosterone production, which is critical in the management of prostate cancer. Debio 4228 is being developed by Debiopharm International.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on Debio 4228.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 4228.

Explore the full profile